1.Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Independent and distinct associations of FABP4 and FABP5 with metabolic parameters in type 2 diabetes mellitus. Front Endocrinol (Lausanne) in press pubmed
2.Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy. Cardiovasc Diabetol 2020;19:89. pubmed
3.Hirai H, Higa M, Morimoto T, Sakuma M, Arasaki O, Nomiyama T, Node K, Ueda S. Shimabukuro M. Dissimilar effects of anagliptin and sitagliptin on lipoprotein subclass in standard or strong statin-treated patients with type 2 diabetes mellitus: a sub-analysis of the REASON Trial. J Clin Med 2020;9:93 pubmed
4.Machii N, Kudo A, Saito H, Tanabe H, Iwasaki M, Hirai H, Masuzaki H, Shimabukuro M. Walking speed is the sole determinant criteria of sarcopenia of mild cognitive impairment in Japanese elderly patients with type 2 diabetes mellitus. J Clin Med 2020;9:2133 pubmed
5.Ma E, Ohira T, Sakai A, Yasumura S, Takahashi A, Kazama J, Shimabukuro M, Nakano H, Okazaki K, Maeda M, Yabe H, Suzuki Y, Kamiya K. Dietary patterns associated with cardiometabolic risks in Japan: the Fukushima Health Management Survey, 2011–2015. Nutrients 2020;12:129pubmed
6.Maimaituxun G, Fukuda D, Izaki H, Hirata H, Kanayama H, Masuzaki H, Sata M, Shimabukuro M. Levels of adiponectin expression in peri-renal and subcutaneous adipose tissue and its determinants in human biopsied samples. Front Endocrinol (Lausanne) in press pubmed
7.Maimaituxun G, Yamada H, Fukuda D, Yagi S, Kusunose K, Hirata Y, Nishio S, Soeki T, Masuzaki H, Sata M, Shimabukuro M. Association of local epicardial adipose tissue depots and left ventricular diastolic performance in patients with preserved left ventricular ejection fraction. Circ J 2020;84:203-216 pubmed
8.Rahadian A, Fukuda D, Salim HM, Yagi S, Kusunose K, Yamada H, Soeki T, Shimabukuro M, Sata M. Thrombin inhibition by dabigatran attenuates endothelial dysfunction in diabetic mice. Vasc Pharmacol 2020;124:106632 pubmed
9.Sakai A, Nakano H, Ohira T, Maeda M, Okazaki K, Takahashi A, Kawasaki Y, Satoh H, Ohtsuru A, Shimabukuro M, Hashimoto S, Hosoya M, Yasumura S, Ohto H, Kamiya K, the Fukushima Health Management Survey Group. Relationship between the prevalence of polycythemia and factors observed in the Mental Health and Lifestyle Survey after the Great East Japan Earthquake. Medicine (Baltimore) 2020;124:106632 pubmed
10.Takahashi A, Ohira T, Okazaki K, Yasumura S, Sakai A, Maeda M, Yabe H, Hosoya M, Ohtsuru A, Kawasaki Y, Suzuki H, Shimabukuro M, Kazama JJ. Hashimoto S, Watanabe K, Nakano H, Hayashi F, Ohto H, Kamiya K, Ohira H. Effects of psychological and lifestyle factors on metabolic syndrome following the fukushima daiichi nuclear power plant accident: The Fukushima Health Management Survey. J Atheroscler Thromb 2020;1010-1018. pubmed
11.Tanabe H, Saito H, Kudo A, Machii N, Hirai H, Maimaituxun G, Tanaka K, Masuzaki H, Watanabe T, Asahi K, Kazama JJ, Shimabukuro M. Factors associated with risk of diabetic complications in novel cluster-based diabetes subgroups: a Japanese retrospective cohort study. J Clin Med 2020;9:2083 pubmed
12.Tanabe H, Saito H, Machii N, Kudo A, Tanaka K, Asahi K, Kazama JJ. Shimabukuro M. Burden of undiagnosed type 2 diabetes in diabetic kidney disease: a japanese retrospective cohort study. J Clin Med 2020;9:2028 pubmed
13.Tanaka, A, Shimabukuro M, Machii N, Teragawa H, Okada Y, Shima K, Takamura T, Taguchi I, Hisauchi I, Toyoda S, Matsuzawa Y, Tomiyama H, Yamaoka-Tojo M, Ueda S, Higashi Y, Node K. Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: the placebo-controlled double-blind randomized EMBLEM trial. J Diabetes Investig 2020;11:1551-1563. pubmed
14.Tanaka A, Shimabukuro M, Okada Y, Sugimoto K, Kurozumi A, Torimoto K, Hirai H, Node K. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial. Cardiovasc Diabetol 2020;19:85 pubmed
15.Teragawa H, Morimoto T, Fujii Y, Ueda T, Sakuma M, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Ueda S. Effect of anagliptin versus sitagliptin on inflammatory markers: outcomes from the REASON Trial. Diabetes Metab Syndr Obes 2020;13:4993–5001. pubmed
16.Yamaguchi S, Abe M, Arakaki T, Arasaki O, Shimabukuro M. Prognostic value of lactate dehydrogenase for mid-term mortality in acute decompensated heart failure: a comparison to established biomarkers and brain natriuretic peptide. Heart Lung Circ 2020;29:1318-1327. pubmed
17.Yamaguchi S, Abe M, Iseki K, Arakaki T, Arasaki O, Shimabukuro M, Ueda S. Prognostic impact of the early changes in serum chloride level among hospitalized acute heart failure patients: A Retrospective Cohort Study. Circ Rep 2020;2:409-419. pubmed
18.Yamaguchi S, Oba K, Higa H, Arasaki O, Shimabukuro M. Age-dependent efficacy of ezetimibe for low-density lipoprotein cholesterol reduction in Japanese patients with or without type 2 diabetes mellitus. J Clin Med 2020;9:1675 pubmed
島袋充生 Metabolic syndrome and dyslipidemia メタボリックシンドロームと糖尿病(翻訳) The ESC Handbook on Cardiovascular Pharmacotherapy (2 Ed) Edited by Juan Carlos Kaski and Keld Per Kjeldsen 欧州心臓病学会(ESC)心血管薬物療法ハンドブック 日本語翻訳版 Oxford Univ Press, 2020, UK
